Manish K. Jha, MD

Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas

  • 12Articles
  • 76.8KReads
  • 2020–2026Active
  • 94Collaborators
  • 182Citations

About

Manish K. Jha, MBBS, is affiliated with the University of Texas Southwestern Medical Center in Dallas, Texas. Jha has contributed to 11 articles published between 2020 and 2025, focusing on topics such as depression, addiction, pain, and posttraumatic stress disorder. Frequent co-authors include George I. Papakostas, Madhukar H. Trivedi, Maurizio Fava, Sanjay J. Mathew, and Dan V. Iosifescu.

Publications

JCP
When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?
ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
Original Research

Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial

July 30, 2025

Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
, , , et al
JCP
Ketamine Infusions and Written Exposure Therapy for Chronic PTSD
Original Research

Ketamine Infusions and Written Exposure Therapy for Chronic PTSD

April 2, 2025

Preliminary findings suggest that the combined treatment may yield large and durable symptom reductions for patients with severe chronic PTSD
, , , et al
JCP
Difficult to Treat Depression: Focus on Approach, Algorithms, and Access
Academic Highlights

Difficult to Treat Depression: Focus on Approach, Algorithms, and Access

November 25, 2024

The Southwest Forum on Difficult to Treat Depression brought together 11 experts to discuss aspects of managing difficult-to-treat depression. This article presents highlights from the forum, covering such topics...
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
Original Research

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
, , , et al
JCP
Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Original Research

Association of Pain with Irritability and Depression

April 13, 2021

Is pain associated with irritability and depression? This study aimed to evaluate relationships between these symptom categories and determine how they may relate to functional impairments.
, , , et al
JCP
Original Research

Adjunctive Pimavanserin and Sleep/Wakefulness in MDD

December 1, 2020

Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
, , , et al
JCP
Original Research

Switching Antidepressants Following SSRI Failure

August 11, 2020

An antidepressant medication switch often follows a failed initial trial with SSRIs. This study sought to determine the probability and timing of both response and remission and the optimal...
, , , et al
JCP
Meta-Analysis

Esketamine Augmentation in Major Depressive Disorder

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe